NO20014837D0 - Pyrazolsammensetninger nyttige som inhibitorer av ERK - Google Patents
Pyrazolsammensetninger nyttige som inhibitorer av ERKInfo
- Publication number
- NO20014837D0 NO20014837D0 NO20014837A NO20014837A NO20014837D0 NO 20014837 D0 NO20014837 D0 NO 20014837D0 NO 20014837 A NO20014837 A NO 20014837A NO 20014837 A NO20014837 A NO 20014837A NO 20014837 D0 NO20014837 D0 NO 20014837D0
- Authority
- NO
- Norway
- Prior art keywords
- erk
- inhibitors
- compositions useful
- pyrazole compositions
- pyrazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18050600P | 2000-02-05 | 2000-02-05 | |
US19195600P | 2000-03-24 | 2000-03-24 | |
US24293500P | 2000-10-24 | 2000-10-24 | |
PCT/US2001/003911 WO2001057022A2 (en) | 2000-02-05 | 2001-02-05 | Pyrazole compositions useful as inhibitors of erk |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20014837D0 true NO20014837D0 (no) | 2001-10-04 |
NO20014837L NO20014837L (no) | 2001-12-04 |
NO322745B1 NO322745B1 (no) | 2006-12-04 |
Family
ID=27391289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20014837A NO322745B1 (no) | 2000-02-05 | 2001-10-04 | Pyrazolforbindelser, sammensetninger inneholdende dem og deres anvendelser, samt fremgangsmate for a hemme proteinkinaseaktivitet. |
Country Status (19)
Country | Link |
---|---|
US (4) | US6528509B1 (no) |
EP (1) | EP1200422A2 (no) |
JP (1) | JP4783532B2 (no) |
KR (1) | KR20010111298A (no) |
CN (1) | CN1362953A (no) |
AU (1) | AU782775B2 (no) |
BG (1) | BG106054A (no) |
BR (1) | BR0104424A (no) |
CA (1) | CA2369504C (no) |
CZ (1) | CZ20013540A3 (no) |
HK (1) | HK1046276A1 (no) |
HU (1) | HUP0202332A2 (no) |
IL (1) | IL145757A (no) |
LT (1) | LT4981B (no) |
NO (1) | NO322745B1 (no) |
NZ (1) | NZ514583A (no) |
SK (1) | SK14082001A3 (no) |
TR (1) | TR200103787T1 (no) |
WO (1) | WO2001057022A2 (no) |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207665B1 (en) * | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
KR20010111298A (ko) * | 2000-02-05 | 2001-12-17 | 버텍스 파마슈티칼스 인코포레이티드 | Erk의 억제제로서 유용한 피라졸 조성물 |
US6436915B1 (en) | 2000-04-07 | 2002-08-20 | Kinetek Pharmaceuticals, Inc. | Pyrazole compounds |
US7074794B2 (en) * | 2000-08-10 | 2006-07-11 | Mitsubishi Pharma Corporation | Proline derivatives and the use thereof as drugs |
US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
JP4105949B2 (ja) * | 2000-09-15 | 2008-06-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
IL154710A0 (en) | 2000-09-15 | 2003-10-31 | Vertex Pharma | Isoxazole derivatives and pharmaceutical compositions containing the same |
US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
AU2001287898A1 (en) * | 2000-09-22 | 2002-04-02 | Stephen Garland | Pyrazolopyridines and pyrazolopyridazines as antidiabetics |
PT1355905E (pt) * | 2000-12-21 | 2007-05-31 | Vertex Pharma | Compostos de pirazole úteis como inibidores de proteínaquinase |
EP1364949A4 (en) | 2001-02-02 | 2005-11-23 | Takeda Pharmaceutical | INHIBITOR OF JNK |
EP1423380B1 (en) | 2001-08-03 | 2010-12-15 | Vertex Pharmaceuticals Incorporated | Pyrazole-derived kinase inhibitors and uses thereof |
DE60226154T2 (de) | 2001-08-03 | 2009-05-20 | Vertex Pharmaceuticals Inc., Cambridge | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung |
WO2003045379A1 (en) | 2001-11-30 | 2003-06-05 | Kinetek Pharmaceuticals, Inc. | Hydrazonopyrazole derivatives and their use as therapeutics |
EP1465610B1 (en) * | 2002-01-10 | 2008-12-31 | F. Hoffmann-La Roche Ag | Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation |
TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
EP1472245A2 (en) * | 2002-02-06 | 2004-11-03 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds useful as inhibitors of gsk-3 |
ATE468336T1 (de) * | 2002-03-15 | 2010-06-15 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
EP1506189A1 (en) | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
ATE360015T1 (de) * | 2002-07-31 | 2007-05-15 | Critical Outcome Technologies | Protein tyrosin kinase inhibitoren |
EA200500299A1 (ru) * | 2002-08-02 | 2005-08-25 | Вертекс Фармасьютикалз Инкорпорейтед | Пиразольные композиции, используемые в качестве ингибиторов gsk-3 |
EP1388541A1 (en) * | 2002-08-09 | 2004-02-11 | Centre National De La Recherche Scientifique (Cnrs) | Pyrrolopyrazines as kinase inhibitors |
AU2003273675A1 (en) * | 2002-10-09 | 2004-05-04 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
WO2004038371A2 (en) * | 2002-10-23 | 2004-05-06 | Exelixis, Inc. | Ccr8 as modifier of branching morphogenesis and methods of use |
BR0317430A (pt) * | 2002-12-20 | 2005-10-25 | Pharmacia Corp | Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno |
US20050019366A1 (en) * | 2002-12-31 | 2005-01-27 | Zeldis Jerome B. | Drug-coated stents and methods of use therefor |
WO2004072029A2 (en) * | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
WO2004078261A1 (en) * | 2003-03-07 | 2004-09-16 | The University Court Of The University Of Aberdeen | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
MXPA06000794A (es) | 2003-07-22 | 2006-08-23 | Astex Therapeutics Ltd | Compuestos 1h-pirazola 3,4-disustituida y su uso como moduladores de quinasas dependientes de ciclina (cdk) y quinasa-3 de sintasa de glicogeno (gsr-3). |
NZ545270A (en) * | 2003-07-30 | 2010-04-30 | Rigel Pharmaceuticals Inc | 2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
AU2004264440B2 (en) | 2003-08-15 | 2008-10-23 | Vertex Pharmaceuticals Incorporated | Pyrrole compositions useful as inhibitors of c-Met |
DE10354060A1 (de) * | 2003-11-19 | 2005-06-02 | Merck Patent Gmbh | Pyrrolderivate |
AU2004297235A1 (en) * | 2003-12-04 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
WO2005061519A1 (en) | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
US7488817B2 (en) * | 2004-02-02 | 2009-02-10 | The Trustees Of The University Of Pennsylvania | Metal complex protein kinase inhibitors |
JP2007530595A (ja) | 2004-03-26 | 2007-11-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | Erk2のピリジンインヒビターおよびそれらの使用 |
JP2007533753A (ja) * | 2004-04-23 | 2007-11-22 | タケダ サン ディエゴ インコーポレイテッド | インドール誘導体及びキナーゼ阻害剤としてのその使用 |
EP1778669A2 (en) * | 2004-08-18 | 2007-05-02 | Takeda San Diego, Inc. | Kinase inhibitors |
FR2876582B1 (fr) * | 2004-10-15 | 2007-01-05 | Centre Nat Rech Scient Cnrse | Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
DE602005023333D1 (de) | 2004-10-15 | 2010-10-14 | Takeda Pharmaceutical | Kinaseinhibitoren |
RU2394825C2 (ru) * | 2004-11-22 | 2010-07-20 | Вертекс Фармасьютикалз Инкорпорейтед | Пирролопиразины, пригодные в качестве ингибиторов киназы аврора а |
BRPI0519759A2 (pt) * | 2004-12-30 | 2009-03-10 | Astex Therapeutics Ltd | composiÇÕes farmacÊuticas |
US20100160324A1 (en) * | 2004-12-30 | 2010-06-24 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
WO2006070202A1 (en) * | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives having kinase modulating activity |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
NZ563454A (en) | 2005-06-08 | 2011-03-31 | Rigel Pharmaceuticals Inc | 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway |
JP2007000061A (ja) * | 2005-06-23 | 2007-01-11 | Sumitomo Chemical Co Ltd | 昆虫由来のc−Junアミノ末端リン酸化酵素活性に関わる有害生物の生理状態に変化を与える薬剤 |
EP1917259B1 (en) * | 2005-08-18 | 2012-01-25 | Vertex Pharmaceuticals Incorporated | Pyrazine kinase inhibitors |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
WO2007056164A2 (en) * | 2005-11-03 | 2007-05-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
ATE527240T1 (de) * | 2005-12-13 | 2011-10-15 | Schering Corp | Polyzyklische indazol-derivate als erk-hemmer |
WO2007077435A1 (en) | 2005-12-30 | 2007-07-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
EP1984331B1 (en) | 2006-02-16 | 2010-10-20 | Schering Corporation | Pyrrolidine derivatives as erk inhibitors |
US8962643B2 (en) | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
TW200800203A (en) | 2006-03-08 | 2008-01-01 | Astrazeneca Ab | New use |
WO2008001115A2 (en) | 2006-06-29 | 2008-01-03 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea |
EP2223925A1 (en) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US20100120717A1 (en) | 2006-10-09 | 2010-05-13 | Brown Jason W | Kinase inhibitors |
JP2010509231A (ja) * | 2006-11-02 | 2010-03-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼの阻害剤として有用なアミノピリジンおよびアミノピリミジン |
ATE474835T1 (de) * | 2006-12-19 | 2010-08-15 | Vertex Pharma | Als inhibitoren von proteinkinasen geeignete aminopyrimidine |
CN101611007A (zh) * | 2006-12-20 | 2009-12-23 | 先灵公司 | 新颖的jnk抑制剂 |
US8034815B2 (en) | 2007-01-11 | 2011-10-11 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
US8420690B2 (en) * | 2007-02-07 | 2013-04-16 | Glaxosmithkline Llc | Inhibitors of Akt activity |
GB0702862D0 (en) * | 2007-02-14 | 2007-03-28 | Univ Aberdeen | Therapeutic compounds |
NZ579485A (en) * | 2007-03-09 | 2012-02-24 | Vertex Pharma | Aminopyrimidines useful as inhibitors of protein kinases |
CA2679884A1 (en) * | 2007-03-09 | 2008-09-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
AU2008226461A1 (en) | 2007-03-09 | 2008-09-18 | Vertex Pharmaceuticals Incorporated | Aminopyridines useful as inhibitors of protein kinases |
WO2008124085A2 (en) * | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
AU2008240313A1 (en) | 2007-04-13 | 2008-10-23 | Aj Park | Aminopyrimidines useful as kinase inhibitors |
CN101801959A (zh) * | 2007-05-02 | 2010-08-11 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的氨基嘧啶类化合物 |
AU2008247592A1 (en) | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
AU2008247595A1 (en) * | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
EP2164842A2 (en) * | 2007-05-24 | 2010-03-24 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
MX2009014208A (es) * | 2007-06-18 | 2010-01-28 | Schering Corp | Compuestos heterociclicos y usos de los mismos como inhibidores de erk. |
EP2176261B1 (en) * | 2007-07-31 | 2012-12-19 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
CA2710039C (en) | 2007-12-26 | 2018-07-03 | Critical Outcome Technologies, Inc. | Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer |
AU2009214440B2 (en) | 2008-02-15 | 2014-09-25 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases |
SG188179A1 (en) | 2008-02-21 | 2013-03-28 | Merck Sharp & Dohme | Compounds that are erk inhibitors |
AU2009244897B2 (en) | 2008-04-16 | 2014-11-13 | Alexion Pharmaceuticals, Inc. | 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
CA2723185A1 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8106039B2 (en) * | 2008-04-30 | 2012-01-31 | The Trustees Of The University Of Pennsylvania | Metal complex phosphatidyl-inositol-3-kinase inhibitors |
EP2306825A4 (en) * | 2008-06-26 | 2011-12-28 | Glaxosmithkline Llc | HAMMER OF ACT ACTIVITY |
EP2303277A4 (en) * | 2008-06-26 | 2011-08-17 | Glaxosmithkline Llc | HAMMER OF ACT ACTIVITY |
JP2011525931A (ja) * | 2008-06-26 | 2011-09-29 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Akt活性の阻害剤 |
WO2010006438A1 (en) | 2008-07-17 | 2010-01-21 | Critical Outcome Technologies Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
JP2012501971A (ja) * | 2008-09-03 | 2012-01-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | 共結晶および共結晶を含む薬学的処方物 |
AU2010281404A1 (en) * | 2009-07-28 | 2012-02-09 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
EP2526097A1 (en) | 2010-01-19 | 2012-11-28 | AstraZeneca AB | Pyrazine derivatives |
CA2999435A1 (en) | 2010-04-01 | 2011-10-06 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
US9102625B2 (en) | 2010-11-01 | 2015-08-11 | Portola Pharmaceuticals, Inc. | Nicotinamides as JAK kinase modulators |
WO2013078466A1 (en) | 2011-11-23 | 2013-05-30 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
EP2903970A4 (en) | 2012-10-08 | 2016-11-30 | Portola Pharm Inc | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS |
WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
WO2015041533A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
WO2015156674A2 (en) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
KR101600579B1 (ko) * | 2014-06-25 | 2016-03-07 | 한국생명공학연구원 | 피라졸 아마이드 화합물 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
CN116854662A (zh) * | 2015-01-30 | 2023-10-10 | 生物医学谷探索股份有限公司 | C21H22Cl2N4O2的晶型 |
EP3355923B1 (en) | 2015-10-01 | 2022-02-23 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Histone deacetylase inhibitors for use in the treatment of drug resistant melanoma |
WO2017099591A1 (en) | 2015-12-07 | 2017-06-15 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treatment of inhibitor resistant braf-mutant cancers |
US10821104B2 (en) * | 2015-12-07 | 2020-11-03 | Suzhou Sinovent Pharmaceuticals Co., Ltd. | Five-membered heterocyclic amides WNT pathway inhibitor |
WO2017204626A1 (en) | 2016-05-24 | 2017-11-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combination therapy - combined map2k4/map3k1 and mek/erk inhibition |
EP3805217A4 (en) * | 2018-06-08 | 2022-03-23 | Betta Pharmaceuticals Co., Ltd | ERK INHIBITOR AND USES THEREOF |
US11739078B2 (en) | 2019-02-22 | 2023-08-29 | Insilico Medicine Ip Limited | Methods of inhibiting kinases |
TW202102511A (zh) | 2019-03-28 | 2021-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 噻吩并雜環類衍生物、其製備方法及其在醫藥上的應用 |
US20220185818A1 (en) | 2019-03-29 | 2022-06-16 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrroloheterocyclic derivative, preparation method therefor, and application thereof in medicine |
EP3978498A1 (en) | 2019-05-24 | 2022-04-06 | Jiangsu Hengrui Medicine Co., Ltd. | Substituted fused bicyclic derivative, preparation method therefor, and application thereof in medicines |
TW202221001A (zh) | 2020-09-29 | 2022-06-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 吡咯並雜環類衍生物的晶型及其製備方法 |
CA3208490A1 (en) | 2021-02-24 | 2022-09-01 | Aleksandrs Zavoronkovs | Analogs for the treatment of disease |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2707295A1 (fr) * | 1993-06-07 | 1995-01-13 | Rhone Poulenc Agrochimie | Fongicides pyrazoles substitués en position 3 par un hétérocycle. |
JP3734180B2 (ja) * | 1994-12-28 | 2006-01-11 | エーザイ株式会社 | 新規ピラゾール誘導体 |
GB9608435D0 (en) * | 1996-04-24 | 1996-06-26 | Celltech Therapeutics Ltd | Chemical compounds |
AR037061A1 (es) * | 1997-05-22 | 2004-10-20 | Searle & Co | Compuesto derivado de pirazol sustituido, procesos para preparar dicho compuesto, composicion farmaceutica que lo contiene y su uso en la preparacion de medicamentos |
CA2288787A1 (en) * | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | Pyrazole derivatives as p38 kinase inhibitors |
US6514977B1 (en) * | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
KR20010111298A (ko) * | 2000-02-05 | 2001-12-17 | 버텍스 파마슈티칼스 인코포레이티드 | Erk의 억제제로서 유용한 피라졸 조성물 |
-
2001
- 2001-02-05 KR KR1020017012710A patent/KR20010111298A/ko not_active Application Discontinuation
- 2001-02-05 CA CA002369504A patent/CA2369504C/en not_active Expired - Fee Related
- 2001-02-05 CN CN01800374A patent/CN1362953A/zh active Pending
- 2001-02-05 IL IL145757A patent/IL145757A/en not_active IP Right Cessation
- 2001-02-05 HU HU0202332A patent/HUP0202332A2/hu unknown
- 2001-02-05 AU AU36723/01A patent/AU782775B2/en not_active Ceased
- 2001-02-05 EP EP01908911A patent/EP1200422A2/en not_active Withdrawn
- 2001-02-05 JP JP2001557854A patent/JP4783532B2/ja not_active Expired - Fee Related
- 2001-02-05 NZ NZ514583A patent/NZ514583A/en unknown
- 2001-02-05 TR TR2001/03787T patent/TR200103787T1/xx unknown
- 2001-02-05 SK SK1408-2001A patent/SK14082001A3/sk unknown
- 2001-02-05 WO PCT/US2001/003911 patent/WO2001057022A2/en active IP Right Grant
- 2001-02-05 CZ CZ20013540A patent/CZ20013540A3/cs unknown
- 2001-02-05 BR BR0104424-9A patent/BR0104424A/pt not_active IP Right Cessation
- 2001-10-04 NO NO20014837A patent/NO322745B1/no not_active IP Right Cessation
- 2001-10-05 US US09/972,437 patent/US6528509B1/en not_active Expired - Lifetime
- 2001-10-17 LT LT2001103A patent/LT4981B/lt not_active IP Right Cessation
- 2001-10-26 BG BG106054A patent/BG106054A/xx unknown
-
2002
- 2002-08-22 US US10/225,719 patent/US6593357B1/en not_active Expired - Lifetime
- 2002-10-16 HK HK02107512.2A patent/HK1046276A1/zh unknown
-
2003
- 2003-01-02 US US10/335,793 patent/US6699865B2/en not_active Expired - Fee Related
- 2003-10-17 US US10/688,613 patent/US7056944B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2369504A1 (en) | 2001-08-09 |
HK1046276A1 (zh) | 2003-01-03 |
NZ514583A (en) | 2004-05-28 |
US7056944B2 (en) | 2006-06-06 |
AU3672301A (en) | 2001-08-14 |
BR0104424A (pt) | 2002-01-08 |
BG106054A (en) | 2002-06-28 |
HUP0202332A2 (en) | 2002-10-28 |
LT4981B (lt) | 2003-01-27 |
US6593357B1 (en) | 2003-07-15 |
US20030040536A1 (en) | 2003-02-27 |
IL145757A0 (en) | 2002-07-25 |
AU782775B2 (en) | 2005-08-25 |
KR20010111298A (ko) | 2001-12-17 |
US6528509B1 (en) | 2003-03-04 |
JP2003522163A (ja) | 2003-07-22 |
WO2001057022A2 (en) | 2001-08-09 |
LT2001103A (en) | 2002-10-25 |
JP4783532B2 (ja) | 2011-09-28 |
NO322745B1 (no) | 2006-12-04 |
TR200103787T1 (tr) | 2002-10-21 |
SK14082001A3 (sk) | 2002-03-05 |
WO2001057022A3 (en) | 2002-03-07 |
IL145757A (en) | 2007-12-03 |
US20040102506A1 (en) | 2004-05-27 |
NO20014837L (no) | 2001-12-04 |
CA2369504C (en) | 2009-01-06 |
EP1200422A2 (en) | 2002-05-02 |
US6699865B2 (en) | 2004-03-02 |
CN1362953A (zh) | 2002-08-07 |
CZ20013540A3 (cs) | 2002-03-13 |
US20030225151A1 (en) | 2003-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20014837L (no) | Pyrazolsammensetninger nyttige som inhibitorer av ERK | |
AU2001236720A1 (en) | Compositions useful as inhibitors of erk | |
NO20030867D0 (no) | Hydroksamderivater anvendelig som deacetylaseinhibitorer | |
NO20032670L (no) | Pyrazolforbindelser nyttige som proteinkinaseinhibitorer | |
NO20031189D0 (no) | Pyrazolforbindelser nyttige som proteinkinaseinhibitorer | |
NO20021042L (no) | Benzofenoner som inhibitorer av reverstranskriptaser | |
NO20033399L (no) | Eterderivater anvendelige som inhibitorer av PDE4-isoenzymer | |
SE0701538L (sv) | Azaspiroalkanderivat som hämmare av metalloproteaser | |
NO20026262D0 (no) | Cyklopentyl-substituerte glutaramidderivater som inhibitorer av nöytral endopeptidase | |
NO20043158L (no) | Substituerte kinazolinderivater som inhibitorer av aurorakinaser | |
NO20043726L (no) | Heteroarylforbindelser anvendelige som inhibitorer av GSK-3 | |
NO20030055L (no) | Colchinolderivater som angiogenese inhibitorer | |
NO20021239L (no) | Pteridinoner som kinase-inhibitorer | |
DK1185529T3 (da) | Pyrazolbenzodiazepiner som CDK2-inhibitorer | |
AU2002305205A1 (en) | 9-deazaguanine derivatives as inhibitors of gsk-3 | |
NO20024997D0 (no) | 2-guanidino-4-arylkinazoliner som NHE-3-inhibitorer | |
NO20025811D0 (no) | Forbindelser som er effektive som beta-2-adrenoreseptor- anonister så vel som PDE4-inhibitorer | |
NO20040996L (no) | Nye forbindelser og sammensetninger som catepsin-inhibitorer | |
NO20021959D0 (no) | Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer | |
NO20031316L (no) | Beleggsammensetninger | |
NO20030820D0 (no) | Anvendelse av vitamin D derivater som benresorpsjons inhibitorer | |
DK1317448T4 (da) | Pyrazolforbindelser anvendelige som proteinkinaseinhibitorer | |
DK1296981T3 (da) | Substituerede pyrrolopyridinonderivater som phosphodiesteraseinhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |